Hilltop Holdings Inc. Cuts Stake in Bristol Myers Squibb Company $BMY

Hilltop Holdings Inc. lessened its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 53.3% during the first quarter, HoldingsChannel reports. The firm owned 25,193 shares of the biopharmaceutical company’s stock after selling 28,810 shares during the period. Hilltop Holdings Inc.’s holdings in Bristol Myers Squibb were worth $1,528,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the stock. Swiss RE Ltd. acquired a new position in Bristol Myers Squibb during the 4th quarter worth approximately $25,000. Darwin Wealth Management LLC acquired a new stake in Bristol Myers Squibb in the second quarter valued at approximately $25,000. Physician Wealth Advisors Inc. grew its position in Bristol Myers Squibb by 73.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 202 shares in the last quarter. Bayban purchased a new stake in shares of Bristol Myers Squibb during the fourth quarter valued at approximately $31,000. Finally, EQ Wealth Advisors LLC acquired a new position in shares of Bristol Myers Squibb during the fourth quarter worth $32,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol Myers Squibb Stock Up 0.9%

BMY stock opened at $62.05 on Friday. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $62.89. The company has a current ratio of 1.42, a quick ratio of 1.28 and a debt-to-equity ratio of 2.10. The company has a market capitalization of $126.70 billion, a P/E ratio of 17.43, a PEG ratio of 0.18 and a beta of 0.23. The firm has a 50 day simple moving average of $57.49 and a 200-day simple moving average of $58.03.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.42 by $0.16. The firm had revenue of $11.49 billion for the quarter, compared to analysts’ expectations of $10.93 billion. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The firm’s quarterly revenue was up 2.6% on a year-over-year basis. During the same period in the prior year, the company posted $1.80 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, equities research analysts predict that Bristol Myers Squibb Company will post 6.34 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, July 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.1%. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 70.79%.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Wall Street Zen upgraded shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 27th. Guggenheim reiterated a “buy” rating and issued a $72.00 price objective on shares of Bristol Myers Squibb in a report on Wednesday, April 8th. Bank of America decreased their price objective on shares of Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating for the company in a research report on Friday, July 10th. Weiss Ratings downgraded Bristol Myers Squibb from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday, July 16th. Finally, Citigroup reaffirmed a “neutral” rating on shares of Bristol Myers Squibb in a research report on Friday, May 1st. Eight research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $61.25.

Bristol Myers Squibb News Roundup

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb announced progress on a new lung cancer combination therapy, advancing the program into Phase 2. That suggests continued pipeline momentum and gives investors another potential long-term growth catalyst. Article Title
• Positive Sentiment: The company also expanded its pipeline with a first-in-human trial for BMS-986533, reinforcing the view that Bristol Myers is still investing in new drug candidates beyond its current blockbuster portfolio. Article Title
• Neutral Sentiment: Multiple previews ahead of Bristol Myers Squibb’s upcoming earnings report point to Wall Street expecting earnings growth and a possible beat, which may be supporting shares ahead of the release. Article Title
• Neutral Sentiment: An analyst note on Bristol Myers Squibb was published, but the headline indicates general commentary rather than a major new thesis change, so the market impact appears limited. Article Title
• Negative Sentiment: Broader healthcare commentary flagged some names to avoid, but Bristol Myers Squibb was not singled out; still, it reflects a mixed sentiment backdrop for the sector rather than a company-specific setback. Article Title

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.